上市药企被举报行贿，涉及上百名医生！最新回应

Core Viewpoint - The article highlights the ongoing corruption issues in the medical industry, particularly focusing on the allegations against Xintian Pharmaceutical Co., Ltd. and its high sales expenses, which may indicate potential commercial bribery risks [2][3][7]. Group 1: Allegations and Investigations - A leaked notification from the Sichuan Provincial Health Commission revealed that over 100 doctors from more than 30 medical institutions are suspected of accepting commercial bribes related to Xintian Pharmaceutical [2]. - The notification mandates local health commissions to investigate and report findings by May 25, 2025, emphasizing the need for compliance with health regulations [5]. - Allegations include the use of false case collections, lavish dinners, and excessive lecture fees to facilitate bribery, with evidence provided in the form of financial records and meeting materials [5][6]. Group 2: Financial Performance and Sales Expenses - Xintian Pharmaceutical's sales expenses have been notably high, with 2024 sales expenses projected at 372 million yuan, accounting for 43.34% of total revenue [3][6]. - Despite a reduction in sales expenses over the past two years, the percentage of sales expenses relative to revenue remains significant, indicating potential underlying issues [6][7]. - The company reported a decline in revenue from 954 million yuan in 2022 to 858 million yuan in 2024, alongside a drop in net profit [8]. Group 3: Compliance and Industry Context - The article emphasizes the importance of compliance in the pharmaceutical industry, especially in light of increasing regulatory scrutiny and anti-corruption efforts [3][10]. - Industry experts suggest that high sales expense ratios often correlate with risks of commercial bribery, highlighting the need for transparent marketing practices [7][10]. - The ongoing anti-corruption campaign has led to significant disciplinary actions within the medical sector, with thousands of cases reported [9].